Filing Flows › Tarsus Pharmaceuticals (TARS) › Q2 2026 › vs Q2 2025
Tarsus Pharmaceuticals (TARS) Q2 2026 vs Q2 2025 (year over year)
Tarsus Pharmaceuticals's revenue rose $71.3M (+69%) from $103M in Q2 2025 to $174M in Q2 2026.
Tarsus Pharmaceuticals, Q2 2026: revenue $174M (+69% year over year), operating margin -11.4%, net loss $18.6M, operating cash flow $61.2M. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 32.9% | -29.6% | +62.5 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $174M | $103M | $71.3M | +69% |
| Other income, net | $4.1M | $1.8M | $2.2M | +121% |
| Net loss | $18.6M | $20.3M | −$1.8M | -9% |
| Costs & expenses | $197M | $125M | $71.7M | +57% |
| Operating costs | $194M | $125M | $69.0M | +55% |
| Income tax | $2.7M | $0 | $2.7M | — |
| Cost of revenue | $12.1M | $6.2M | $5.9M | +94% |
| Research & development | $31.0M | $15.6M | $15.4M | +99% |
| SG&A | $151M | $103M | $47.7M | +46% |
| Operating cash sources | $79.8M | −$9.0M | $88.8M | — |
| Depreciation & amortization | $1.0M | $400K | $600K | +150% |
| Share-based compensation | $13.3M | $8.2M | $5.1M | +61% |
| Working capital & other | $65.5M | −$17.7M | $83.2M | — |
| Net loss absorbed | $18.6M | $20.3M | −$1.8M | -9% |
| Operating cash flow | $61.2M | −$29.4M | $90.6M | — |
| Free cash flow (OCF − capex) | $57.2M | −$30.4M | $87.5M | — |
| Capital expenditures | $4.1M | $1.0M | $3.1M | +306% |
Questions
How much did Tarsus Pharmaceuticals's revenue grow year over year in Q2 2026?
Tarsus Pharmaceuticals's revenue rose $71.3M (+69%) from $103M in Q2 2025 to $174M in Q2 2026.